CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cullinan Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$13.98+1.05 (+8.12%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Cullinan Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Market Cap | $899.68M | $197.05M |
| Enterprise Value | $565.18M | $106.56M |
Income (trailing twelve months)
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$241.65M | -$21.44M |
| Net Income | -$219.88M | -$22.46M |
| EBITDA | -$241.34M | -$16.91M |
Returns
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -44.7% | -53.1% |
| Return on Assets (ROA) | -49.7% | -41.0% |
| Return on Invested Capital (ROIC) | -84.2% | -32.0% |
| Return on Capital Employed (ROCE) | -74.8% | -37.8% |
Balance sheet
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $334.50M | $62.42M |
| Net Cash (Debt) | $334.50M | $15.68M |
| Net Cash Per Share | $5.20 | $0.65 |
| Working Capital | $301.35M | $75.77M |
Financial position
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 8.42 | 3.30 |
| Quick Ratio | 8.23 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$175.75M | -$12.35M |
| Capital Expenditures | -$49.00K | -$1.06M |
| Free Cash Flow | -$175.80M | -$20.28M |
| FCF Per Share | -$2.73 | -$0.41 |
Efficiency
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.02M | -$732.08K |
| Employee Count | 109 | 73 |
Dividends and yields
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -24.4% | -21.2% |
| FCF Yield | -19.5% | -7.64% |
| Buyback Yield | 0.00% | -0.58% |
| Shareholder Yield | 0.00% | 0.00% |
Shares
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 64,354,700 | 59,128,900 |
| Shares Change (QoQ) | 4.71% | 0.54% |
| Float | 57,326,500 | 48,744,500 |
| Shares Held by Insiders | 10.9% | 11.8% |
| Shares Held by Institutions | 111.4% | 59.4% |
Scores
| Measure | Cullinan Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 8.98 | 0.10 |
Calculated by StockData from Cullinan Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.